FDA Clears Nocturnal IOP Device
Balance Ophthalmics gains FDA 510(k) clearance for wireless FSYX glaucoma device
Clinical Scorecard: FDA Clears Nocturnal IOP Device
At a Glance
| Category | Detail |
|---|
| Condition | Open-Angle Glaucoma |
| Key Mechanisms | Wireless-enabled ocular pressure adjusting pump designed to lower intraocular pressure during sleep. |
| Target Population | Adults with open-angle glaucoma. |
| Care Setting | Home use alongside existing glaucoma treatments. |
Key Highlights
- FSYX system is the first device specifically for nocturnal IOP reduction.
- Demonstrated a 39% mean reduction in nighttime eye pressure across 12 clinical studies.
- No device-related serious adverse events reported.
- Wireless communication allows for real-world patient usage data access.
- Expected availability to eye care practices in Q4 2026.
Guideline-Based Recommendations
Diagnosis
Management
- Use alongside existing glaucoma treatments, including prior surgical interventions.
Monitoring & Follow-up
- Wireless capability provides insight into patient behavior outside the clinic.
Risks
Patient & Prescribing Data
Adults with open-angle glaucoma.
Device designed to protect patients during nighttime when IOP is highest.
Clinical Best Practices
- Evaluate patient usage data to ensure effective therapy.
- Consider the device as part of a comprehensive glaucoma management plan.
Related Resources & Content
